A randomized, phase II, multicenter, double-blind, place

Project: Research project

Description

A randomized, phase II, multicenter, double-blind, placebo-controlled study evaluating the efficacy and safety of Onartuzumab (Met MAb) in combination with Paclitaxel + Cisplatin or Carboplatin as first-line treatment
StatusFinished
Effective start/end date9/15/129/30/16

Funding

  • Genentech Inc.

Fingerprint

Carboplatin
Placebos
Safety
Therapeutics
onartuzumab
TP protocol